Category Archives: Blog

In antibody drug development, early discovery is often the most time-consuming stage. Immunization, screening, validation, and sequence processing can delay a project by weeks or even months, affecting program initiation, partnership timing, and competitive positioning.

In November 2025, business development (BD) activities in the biopharmaceutical industry slowed slightly compared with October, yet the month still delivered several high-value and strategically important deals. Overall, November’s BD landscape can be summarized by two major themes: large-scale M&A and high-impact licensing agreements. Global pharma companies pursued acquisitions to strengthen pipelines in rare diseases, […]

Using multiple recombinant protein fragments from the same target—such as extracellular domains, functional regions, and membrane-proximal segments—has become an essential strategy in therapeutic antibody discovery. This approach improves epitope diversity, enhances screening accuracy, reduces conformational bias, and accelerates the identification of high-value antibodies including blockers, agonists, and internalizing antibodies.

In recent years, nanobodies (single-domain antibodies, VHHs) have rapidly emerged as a hot research direction in antibody and biologics development, thanks to their unique structure and biological properties. Derived from camelids, these single-domain antibodies feature a small size, high stability, and easy engineering capabilities, making them ideal for applications in drug discovery, diagnostics, imaging, and immunotherapy.

Membrane proteins are molecules that are critically important for life, undertaking key functions such as signal transduction, material transport, and cell recognition. With the deepening of drug development and structural biology research, membrane proteins have become central targets for new drug discovery and mechanistic studies. However, due to their structural complexity and poor stability, their […]

Explore how recombinant proteins derived from human, mouse, monkey, and dog enable more accurate antigen selection, cross-species validation, and improved antibody discovery. Learn why multi-species antigens are essential for screening, affinity evaluation, and translational drug development.

On January 10, Harbour BioMed and Kelun-Biotech out-licensed the overseas rights of their jointly developed TSLP antibody HBM9378/SKB378 to Windward Bio. The deal reached a total value of up to USD 970 million. HBM9378/SKB378 is a fully human anti-TSLP monoclonal antibody co-developed by Harbour BioMed and Kelun-Biotech, designed to regulate immune responses by inhibiting the thymic […]